JPRN-UMIN000005391已完成2 期
Bevacizumab treatment of intra-venous administration and diagnostic nuclear medicine for symptomatic radiation necrosis in the brain - Bevacizumab treatment for symptomatic radiation necrosis
Department of Neurosurgery, Osaka Medical College0 个研究点目标入组 40 人开始时间: 2011年4月7日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients are able to undertake necrotomy; Intracranial tumors are active and recurrent (L/N ratio on F-BPA-PET is greater than 2.5, or L/N ration on C-MET-PET is greater than 1.8; Patients require intravenous administration of antibiotics, antiviral drugs, and antifugal drugs for infection; Febrile patients more than 38 degree Celsius of body temperature or equal; Patients having severe comorbidities such as heart diseases, pulmonary fibrosis, interstitial pneumonia, hemorrhagic diathesis, uncontrollable hypertension or diabetes; *Comorbidity or history of unstable angina and myocardiac infarction within 6 months *Uncontrollable peptic ulcer *Uncontrollable hypertension *Unhealed advanced wound or fracture *Comorbidity or history of gastrointestinal perforation and fistula, and abdominal abscess within 6 months *Comorbidity or history of emoptysis and pulmonary hemorrhage greater than Grade 1 *Comorbidity or history of vascular diseases (venous and arterial thrombosis and embolism, aortic aneurysms) required interventions within 6 months *Congestive heart failure more than NYHA class I *Patients with a schedule of an operation during this study or patients having had an operation within 4 weeks; Patients with hemorrhage (intracranial hemorrhage, gastrointestinal hemorrhage, urinary hemorrhage, hemoptysis); PT-INR is greater than 2.5 or unstable when warfarinization; History of severe hypersensitivity or allergy to bevacizumab; Pregnant patients, patients with a possibility of pregnancy, or patients breastfeeding; Investigators judge patients who are inappropriate to include this study.
研究者
相似试验
已完成
不适用
The intravitreal injection of Bevacizumab for retinopathy of prematurityretinopathy of prematurityJPRN-UMIN000028770Department of Ophthalmology, Shiga University of Medical Science24
已完成
不适用
ow dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathyProliferative diabetic retinopathyJPRN-UMIN000007482Division of Ophthalmology, Department of Visual Sciences, Surugadai-Hospital, Nihon University.60
已完成
2 期
effect of Bevacizumab alone or in combination with 1 mg Triamcinolone for treatment of diabetic retina swellingDiabetic retinopathyDiabetic Macular Edema.IRCT2014080818733N1vice-chancellor for research-Tehran University of Medical Science50
已完成
不适用
Intravitreal bevacizumab injection for intraocular neovascularization in childreRetinopathy of prematurityJPRN-UMIN000014316Kansai Medical University15
进行中（未招募）
不适用
INTRAVITREAL BEVACIZUMAB INJECTION VS. CONVENTIONAL LASER SURGERY FOR VISION-THREATENING RETINOPATHY OF PREMATURITY. - NDEUCTR2009-012609-20-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI